

wherein


 R^1 represents a saturated a iphatic $C_{1\sim15}$ hydrocarbon group optionally substituted with to 3 hydroxy or protected hydroxy groups; and

 R^2 represents a saturated aliphatic C_{2-4} alkyl or C_{1-3} hydroxyalkyl group optionally substituted with one or more substituents, which may be the same or different and which are selected from the group consisting of a hydroxy group, a halogen atom, a cyano group, a lower alkoxy group, an amino group and an acylamino group, provided that when R^2 represents a saturated a iphatic C_1 hydrocarbon group, R^2 is substituted with at least one substituent.

Please amend claim 2 as follows:

 λ (Amended) The vitamin D derivative of

claim 1 which is represented by Formula (II):



wherein

 R^1 represents a saturated aliphatic $C_{1\sim 15}$ hydrocarbon group optionally substituted with 1 to 3 hydroxy or protected hydroxy groups; and

 R^2 represents a C_{2-4} alkyl or C_{1-3} hydroxyalkyl group optionally substituted with one or more substituents, which may be the same or different and which are selected from the group consisting of a hydroxy group, a halogen atom, a cyano group, a lower alkoxy group, an amino group and an acylamino group, provided that when R^2 represents a saturated aliphatic C_1 hydrocarbon group, R^2 is substituted with at least one substituent.

Please amend claim 3 as follows:

(Amended) The vitamin D derivative of claim 1 which is represented by Formula (III):

 $ar{\mathsf{R}^2}$

(III)

wherein

но,,,,

 R^1 represents a saturated aliphatic $C_{1\sim15}$ hydrocarbon group optionally substituted with 1 to 3 hydroxy or protected hydroxy groups; and

OH

 R^2 represents a saturated aliphatic C_{2-4} alkyl is a C_{1-3} hydroxyalkyl group optionally substituted with one or more substituents, which may be the same of different and which are selected from the group consisting of a hydroxy group, a halogen atom, a cyano group, a lower alkoxy group, an amino group and an acylamino group, provided that when R^2 represents a saturated aliphatic

In re Appl. No. 10/069,483 Confirmation No. 3430

 C_1 hydrocarbon group, R^2 is substituted with at least one substituent.

Brita

Please amend claim 4 as follows: 7

4. (Amended) The vitamin D derivative according to one of claims 1 to 3, wherein R² is a hydroxymethyl group, a hydroxyethyl group, a hydroxypropyl group, an ethyl group, a propyl group, or butyl group.

Please amend claim 6 as follows:

(Amended) The vitamin D derivative

(5Z,7E)-(1S,2S,3R,20R)-9,10-seco-5,7,10(19)cholestatriene-2-hydroxymethyl-1,3,25-triol,
(5Z,7E)-(1S,2S,3R,20R)-9,10-seco-5,7,10(19)cholestatriene-2-(2'-hydroxyethyl)-1,3,25-triol,
(5Z,7E)-(1S,2S,3R,20R)-9,10-seco-5,7,10(19)cholestatriene-2-(3'-hydroxypropyl)-1,3,25-triol,
(5Z,7E)-(1S,2S,3R,20R)-9,10-seco-5,7,10(19)cholestatriene-2-ethyl-1,3,25-triol,
(5Z,7E)-(1S,2S,3R,20R)-9,10-seco-5,7,10(19)cholestatriene-2-propyl-1,3,25-triol, and

B3 Covital

In re Appl. No. 10/069,483 Confirmation No. 3430

(5Z,7E)-(1S,2S,3R,20R)-9,10-seco-5,7,10(19)cholestatriene-2-butyl-1,3,25-triol.

Please amend claim 8 as follows: J

BH

8. (Amended) The pharmaceutical composition according to claim 7, wherein the composition includes an effective amount of a vitamin D derivative according to any one of claims 1 to 6 as an active ingredient for a disease associated with abnormal calcium metabolism, an antitumor agent or an immunomodulator.

Please amend claim 13 as follows:

B5

13. (Amended) The pharmaceutical composition according to claim 10, comprising an effective amount of a therapeutic agent for a disease associated with abnormal calcium metabolism, an antitumor agent or an immunomodulator.

Please amend claim 14 as follows:

14. (Amended) The pharmaceutical composition according to claim 11, comprising an effective amount of a therapeutic agent for a disease associated with abnormal calcium metabolism, an antitumor agent or an immunomodulator.

In re Appl. No. 10/069,481 Confirmation No. 3430

B5 that

Please amend claim 15 as follows:

15. (Amended) The pharmaceutical composition according to claim 12, comprising an effective amount of a therapeutic agent for a disease associated with abnormal calcium metabolism, an antitumor agent or an immunomodulator.